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Abstract 
Background: Thyroid hormones have been associated with renal dysfunction in cross-sectional studies. However, 
prospective studies exploring the effect of thyroid hormones on renal function decline were sparse and got contra-
dictive results. We aimed to prospectively explore the associations of thyroid hormones with incident chronic kidney 
disease (CKD) and rapid decline in estimated glomerular filtration rate (eGFR) in Chinese adults.
Methods: The participants were from a community-based cohort including 2103 individuals aged 40 years or above 
without CKD at baseline. Thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxin (FT4) 
were measured by radioimmunoassay at baseline. Serum creatinine, urinary creatinine and albumin were measured 
at baseline and follow-up. CKD was defined as eGFR <60 ml/min/1.73 m2 or urinary albumin-to-creatinine ratio 
≥30 mg/g. Rapid eGFR decline was defined as an annual eGFR decline >3 ml/min/1.73 m2.
Results: During 4 years of follow-up, 198 participants developed CKD and 165 experienced rapid eGFR decline. 
Compared to tertile 1, tertile 3 of FT4 levels were associated with 1.88-folds (95% confidence interval [CI], 1.27–2.77) 
increased risk of incident CKD; and 1.64-folds (95% CI, 1.07–2.50) increased risk of rapid eGFR decline (both P for trend 
≤0.02), after adjustment for confounders. Each 1-pmol/l of FT4 was associated with 12% increased risk of incident 
CKD and 10% of rapid eGFR decline. Among the incident CKD individuals, FT4 was significantly associated with higher 
risk of concurrent complications and further outcomes of CKD. We did not find associations of FT3 or TSH with CKD or 
rapid eGFR decline.
Conclusions: Higher FT4, but not TSH and FT3, was associated with increased risk of incident CKD and rapid eGFR 
decline in middle-aged and elderly Chinese.
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Background
Chronic kidney disease (CKD) is manifested as the pres-
ence of albuminuria, impaired glomerular filtration rate, 
or both [1]. It has been found to be associated with an 
increased risk of cardiovascular morbidity and mortal-
ity, bringing heavy social and economic burden sub-
sequently [2–4]. Now, CKD is affecting approximately 
13.1% of Americans and 10.8% of Chinese adults [5, 6]. 
Although diabetes, hypertension, and family history of 
CKD, etc., have been established as risk factors for CKD 
[7, 8], disclosure of more novel risk factors for CKD or 
decline in estimated glomerular filtration rate (eGFR), 




*Correspondence:  xm11487@rjh.com.cn 
†Xiaolin Huang and Lin Ding contributed equally to this manuscript 
2 Department of Endocrine and Metabolic Diseases, Shanghai Institute 
of Endocrine and Metabolic Diseases, Rui-Jin Hospital, Shanghai Jiao-Tong 
University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai 200025, 
China
Full list of author information is available at the end of the article
Page 2 of 9Huang et al. J Transl Med  (2016) 14:336 
help extensively understand the pathogenesis of CKD 
and develop new prevention strategies for CKD.
Thyroid hormones, which are crucial for regulation of 
human body’s physiological actions, were found influ-
encing GFR, renal blood flow, tubular secretory and re-
absorptive processes as well [10–12]. Previous studies 
reported that overt and subclinical hypothyroidism were 
associated with higher levels of serum creatinine, reduced 
eGFR and increased risk of CKD [13–16]. Hyperthyroid-
ism, however, can also lead to or accelerate the devel-
opment of CKD [17]. In fact, most of the evidence was 
derived from cross-sectional studies [18, 19]. Prospective 
studies exploring the effect of thyroid hormones on renal 
function decline were sparse and got contradictive results 
[20, 21]. One study showed that normal-to-high levels of 
thyroid-stimulating hormone (TSH) and normal-to-low 
levels of free triiodothyronine (FT3) were associated with 
an increased risk of incident CKD in euthyroid individu-
als [20]. While the other reported non-significant asso-
ciation between thyroid dysfunction and changes in renal 
function among older adults [21].
In the present investigation, we aimed to explore pro-
spectively the associations of thyroid hormones with risk 
of incident CKD and rapid eGFR decline; in addition, we 
examined the associations with predicted risks for con-
current complications and further outcomes of CKD, 
among the incident CKD participants.
Methods
Study population and design
All participants of the present study were recruited from 
Songnan Community, Baoshan district, Shanghai, in two 
stages as reported previously [22, 23]. In stage 1, 10,185 
residents aged 40 years old or above were enrolled to the 
screening examination in June and July 2008. Accord-
ing to different levels of fasting plasma glucose (FPG), all 
participants were categorized into three groups: normal 
glucose regulation, impaired glucose regulation and dia-
betes. In stage 2, from June to August 2009, 4012 partici-
pants were randomly selected from the three groups on a 
ratio of 1.44 (normal glucose regulation) to 1.2 (impaired 
glucose regulation) to 1.0 (diabetes) because subjects 
with lower glucose levels were expected to have a lower 
participation rate than those with higher glucose levels, 
for a more comprehensive survey.
Among the 4012 participants, 3455 participants had 
both blood and urine samples. For the present analysis, 
participants were excluded sequentially as follows, with 
a history of thyroid dysfunction (history of overt hyper-
thyroidism, hypothyroidism or thyroiditis, taking or had 
previously taken thyroxine or antithyroid drugs, n = 12), 
currently taking medications which affecting thyroid 
function (n = 5), with a history of thyroidectomy (n = 2), 
with inadequate sample for thyroid measurements 
(n = 42), with missing data on serum creatinine, urinary 
creatinine and albumin (n = 3), and with eGFR <60 ml/
min/1.73 m2 (n = 205) or urinary albumin-to-creatinine 
ratio (ACR) ≥30  mg/g (n =  309). After exclusion, 2877 
participants were eligible. From March to June 2013, all 
the 2877 participants were invited to have a follow-up 
study. 26 participants died during the follow-up. Eventu-
ally, 2103 participants responded and participated in the 
follow-up study (details on Fig. 1).
Written informed consent was obtained by each partic-
ipant and the study protocol was approved by the Institu-
tional Review Board of Rui-Jin Hospital.
Data collection
A questionnaire survey and anthropometric measure-
ments were conducted both at the baseline and fol-
low-up visit. Sociodemographics, lifestyle factors and 
medical history were collected by trained physicians with 
a standard questionnaire via face-to-face interview. Cur-
rent drinkers and smokers were defined as those who 
consumed alcohol at least once a week, and those who 
smoked a cigarette per day or seven cigarettes per week in 
the past 6 months, respectively. The information on body 
weight and height was measured with participants wear-
ing light weight clothing and no shoes. Body mass index 
(BMI) was calculated as weight in kilograms divided 
into squared height in meters. Waist circumference was 
measured at umbilical level in a standing position. After 
at least 5  min rest, blood pressure was measured three 
times with 1-min interval using an automated electronic 
device (OMRON Model HEM-752 FUZZY, Omron 
Company, Dalian, China), at the non-dominant arm in 
a seated position. The average of the three readings was 
used for analysis.
Biochemical measurements
After an at least 10  h overnight fast, the venous sam-
ple was collected and a 75-g oral glucose tolerance test 
(OGTT) was performed for each participant both at the 
baseline and follow-up visit. Levels of serum triglycer-
ide, high-density lipoprotein cholesterol (HDL-c), low-
density lipoprotein cholesterol (LDL-c), total cholesterol 
(TC), and serum creatinine (Cr) were measured by an 
autoanalyser (ADVIA-1650 Chemistry System, Bayer 
Corporation, Germany). FPG and OGTT 2-h plasma 
glucose were measured with using the glucose oxidase 
method on an autoanalyser (ADVIA-1650 Chemistry 
System, Bayer Corporation, Germany), and hemoglobin 
A1c (HbA1c) was determined by high-performance liq-
uid chromatography (BIO-RAD D-10, USA). eGFR was 
evaluated using the 2009 chronic kidney disease epidemi-
ology collaboration (CKD-EPI) equation [24] according 
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to the recommendation in the 2012 kidney disease: 
improving global outcomes (KDIGO) clinical practice 
guideline for the evaluation and management of CKD [1]:
(1) Females: Cr ≤ 0.7 mg/dl, eGFR = 144 × (Cr/0.7)−0.329 × 
(0.993)age; Cr > 0.7 mg/dl, eGFR = 144 × (Cr/0.7)−1.209 × (0.9
93)age. (2) Males: Cr ≤ 0.9 mg/dl, eGFR = 141 × (Cr/0.9)−0.411  
× (0.993)age; Cr > 0.9mg/dl, eGFR = 141 × (Cr/0.9)−1.209 ×  
(0.993)age.
A first-voided, early-morning spot urine was collected 
to measure the urinary albumin and creatinine using rate 
nephelometry (Beckman Coulter, Fullerton, CA) and 
alkaline nitroxanthic acid method, respectively. Urinary 
ACR was calculated as milligrams of urinary albumin 
excretion per gram of urinary creatinine.
Participants selected for a comprehensive 
survey from Songnan Community in 2009 with 
both blood and urine samples (n = 3455)
Death in follow-up duration (n = 26) 
Final participants included in the current 
analysis (n = 2103)
Exclusions (n = 61)
History of overt hyperthyroidism, hypothyroidism or thyroiditis and
taking, or had previously taken thyroid hormones or antithyroid drugs
 (n = 12) Taking medications affecting thyroid function (n = 5)
History of thyroidectomy (n = 2)
Inadequatesample for thyroid measurements (n = 42)
Potential participants (n = 3394) 
Exclusions (n = 517)
Missing data on serum creatinine, urinary creatinine and albumin at 
baseline (n = 3)
eGFR < 60 ml/min/1.73m2 at baseline (n = 205)
Urinary ACR ≥ 30 mg/g at baseline (n = 309) 
Participants invited for follow-up study (n = 2877) 
Participants lost to the follow-up study 
(n = 748) 
Fig. 1 Flow chart of study participants. eGFR estimated glomerular filtration rate, ACR albumin–creatinine-ratio
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Measurements of thyroid function
Levels of serum free thyroxin (FT4), FT3, TSH, thyroid 
peroxidase antibody (TPOAb) and thyroglobulin anti-
body (TGAb) were measured at the baseline by the Clini-
cal Laboratory for Endocrinology, Shanghai Institution 
of Endocrine and Metabolic Disease, which was certified 
by College of American Pathologists, and assessed using 
chemiluminescent microparticle immunoassay method 
by Architect system (Abbott Laboratories, Abbott Park, 
IL). The reference ranges of FT4, FT3 and TSH were 
9.01–19.04 pmol/l, 2.62–6.49 pmol/l and 0.35–4.94 μIU/
ml, respectively, with the corresponding inter-assay 
coefficients of variations (CV) of 2.6–5.3%, 4.7–8.0%, 
and 3.1–3.4%. The reference range was <5.61  IU/ml for 
TPOAb with an inter-assay CV of 4.3–6.8% and <4.11 IU/
ml for TGAb with an inter-assay CV of 3.2–5.2% [23, 25].
Outcomes
In present study, the primary outcome was incident 
CKD which was defined as the presence of eGFR <60 ml/
min/1.73  m2 or urinary ACR ≥30  mg/g at the follow-
up visit [26]. The secondary outcome was rapid eGFR 
decline which was defined as an annual decline [(eGFR at 
follow up—eGFR at baseline)/follow-up period (years)] in 
eGFR >3 ml/min/1.73 m2 [27].
Furthermore, among the participants who developed 
CKD, we predicted the risks of concurrent complications 
and further outcomes of CKD by combining eGFR with 
albuminuria in the 2012 KDIGO clinical practice guide-
line for the evaluation and management of CKD [1]. It 
was classified into four colored risk zones for prognosis: 
low risk, green; moderately increased risk, yellow; high 
risk, orange; and very high risk, red.
Statistics analysis
All statistical analyses were performed by using SAS ver-
sion 9.3 (SAS Institute Inc, Cary, NC, USA). The values 
of serum TSH, TPOAb, TGAb, triglyceride, FPG and 
HbA1c, and urinary ACR were normalized by logarith-
mic transformation because of skewed distributions. 
Continuous variables were shown as means  ±  stand-
ard deviations (SDs) for those with normal distribution 
and were shown as medians (interquartile ranges) for 
those with skewed distribution. All categorical variables 
were presented as numbers (proportions). Thyroid func-
tion measurements were treated as continuous variables 
with one-unit increase or categorical variables by ter-
tiles: <13.60, 13.60–14.83 and ≥14.84  pmol/l for serum 
FT4; <4.43, 4.43–4.83 and ≥4.84 pmol/l for serum FT3; 
<1.151, 1.151–1.860 and ≥1.861 μIU/ml for serum TSH.
Comparisons of baseline characteristics between non-
CKD and incident CKD individuals were performed by 
using t test for continuous variables and Chi-square test 
for categorical variables. P values for trend for percent-
ages of incident CKD and rapid eGFR decline were tested 
by using Cochran–Mantel–Haenszel (CMH) method 
among tertiles of serum FT4.
Multivariable logistic regression analysis was used to 
evaluate the associations of serum FT4, as well as serum 
FT3 and TSH, with the development of CKD and rapid 
eGFR decline. In model 1, age, sex and BMI at baseline 
were adjusted; in model 2, triglyceride, HDL-c, urinary 
ACR (for incident CKD only) and eGFR, current smok-
ing and drinking, diabetes and hypertension status, and 
usage of antidiabetic or antihypertensive drugs at base-
line were further adjusted based on model 1; in model 
3, serum TPOAb and TGAb levels at baseline were fur-
ther adjusted based on model 2. Additionally, we used 
the multinomial logit regression analysis to evaluate the 
associations of baseline serum FT4 levels with the pre-
dicted risks for future outcomes of CKD, among incident 
CKD individuals.
Significance tests were two-tailed and a P value less 
than 0.05 was considered to be statistically significant.
Results
Characteristics of the participants at baseline
A total of 2103 participants free of CKD at baseline 
were included in current analyses. The mean age was 
59.3 years old and 39.3% were males. During the 4-year 
follow-up period, 198 (9.4%) participants developed CKD 
and 165 (7.8%) experienced rapid eGFR decline. Table 1 
shows baseline characteristics of the participants accord-
ing to incident CKD status. Participants who developed 
CKD were older, had higher BMI, waist circumference, 
blood pressure, serum triglyceride, FPG, HbA1c and uri-
nary ACR, and lower level of eGFR (all P values <0.05). 
26.3% of those who developed CKD at follow-up were 
taking antidiabetic drugs and 31.8% were using antihy-
pertensive drugs, significantly higher than that of non-
CKD participants (all P values <0.05). In particular, levels 
of serum FT4, but not FT3 and TSH, were higher among 
the incident CKD participants than non-CKD ones 
(P < 0.0001). No significant differences were observed in 
levels of HDL-c, LDL-c, TC, TPOAb, TGAb, sex distribu-
tion, or status of current smoking and drinking at base-
line between incident CKD and non-CKD participants.
Association of thyroid hormones with incident CKD
The incidence of CKD gradually increased according to 
serum FT4 tertiles: 6.7, 8.6 and 12.9% for tertile 1, ter-
tile 2 and tertile 3, respectively. As compared to tertile 1, 
tertile 3 of FT4 levels was associated with 88% increased 
risk of developing CKD (95% confidence interval [CI] 
1.27–2.77; P for trend = 0.001), after adjustment for the 
confounding factors (Model 3). The continuous variable 
Page 5 of 9Huang et al. J Transl Med  (2016) 14:336 
analysis showed similar results. Each 1-pmol/l of FT4 was 
associated with 12% (95% CI 1.05–1.20) increased risk of 
incident CKD. We did not found a significant association 
between serum FT3 or TSH and incident CKD (Table 2).
Association of thyroid hormones with rapid eGFR decline 
during follow‑up
During follow-up, the eGFR levels of non-CKD indi-
viduals significantly increased, while those of incident 
CKD participants were decreased (all P values <0.05). 
In follow-up study, eGFR of non-CKD and incident 
CKD individuals were 93.0 ±  10.6 and 84.1 ±  18.1  ml/
min/1.73 m2, respectively. With the increment of serum 
FT4 tertiles, the percentages of rapid eGFR decline 
gradually increased (P for trend = 0.0004). Multivariable 
logistic regressions showed that the odds ratio (OR) for 
rapid eGFR decline in the highest FT4 tertile versus the 
lowest tertile was 1.64 (95% CI 1.07–2.50), after adjust-
ment for various confounders. Each 1-pmol/l increase 
of serum FT4 was associated with 10% increased risk of 
rapid eGFR decline. We did not found a significant asso-
ciation between serum FT3 or TSH and risk of rapid 
eGFR decline (Table 3).
Association of baseline serum FT4 levels with the predicted 
risks for future outcomes of CKD
According to the recommendations in the 2012 KDIGO 
clinical practice guideline for the evaluation and man-
agement of CKD [1], among the 198 participants who 
developed CKD during follow-up, 177 participants were 
at moderately increased risk of concurrent complications 
and further outcomes of CKD, 17 and 4 were at high risk 
and very high risk, respectively.
Table 4 shows associations of baseline serum FT4 lev-
els with the predicted risks for future outcomes of CKD, 
among incident CKD individuals. After adjusting for 
a wide range of covariates, each 1-pmol/l increase and 
each 1-tertile increase of FT4 associated 11% and 30% 
increased risk for moderately increased risk of con-
current complications and further outcomes of CKD, 
respectively; and 22% and 161% increased risk for the 
combined high and very high increased risk of concur-
rent complications and further outcomes among incident 
CKD individuals, respectively.
Discussion
In this community-based prospective investigation, we 
found that high levels of serum FT4 significantly asso-
ciated with renal function decline in middle-aged and 
elderly Chinese. Major findings in our study were: (1) 
elevated levels of serum FT4 at baseline associated with 
increased risk of incident CKD and rapid eGFR decline; 
(2) serum FT4 positively associated with the increased 
risk for concurrent complications and further outcomes 
of CKD; (3) no significant associations of serum FT3, 
TSH with incident CKD or rapid eGFR decline were 
found in the present analysis.
In our study, we reported significant associations of 
FT4 with both incident CKD and rapid eGFR decline in a 
large general Chinese population, suggesting that when a 
higher FT4 level was found in clinical practice, a screen-
ing for kidney disease is warranted beyond hyperthyroid-
ism treatments and the thyroid function monitoring. Our 
results were consistent with several previous findings. A 
prospective study focusing on thyroid function status and 
renal function in older persons found that overt hypothy-
roidism provided a protective effect on changes in renal 
Table 1 Baseline characteristics of the participants accord-
ing to incident CKD status
P values are calculated by t test for continuous variables and Chi-square test for 
categorical variables
Data are means ± standard deviations or medians (interquartile ranges) for 
continuous variables, and numbers (proportions) for categorical variables
ACR albumin-to-creatinine ratio, BMI body mass index, DBP diastolic blood 
pressure, eGFR estimated glomerular filtration rate, FT3 free triiodothyronine, 
FT4 free thyroxine, FPG fasting plasma glucose, HDL-c high-density lipoprotein 
cholesterol, HbA1c hemoglobin A1c, LDL-c low-density lipoprotein cholesterol, 
SBP systolic blood pressure, TSH thyroid-stimulating hormone, TPOAb thyroid 
peroxidase antibody, TGAb thyroglobulin antibody
Characteristics Non‑CKD Incident CKD P value
n, % 1905 (90.6) 198 (9.4) –
Age (years) 58.9 ± 8.9 63.1 ± 10.1 <0.0001
Male (n, %) 753 (39.5) 73 (36.9) 0.47
BMI (kg/m2) 24.7 ± 3.4 25.5 ± 3.8 0.0006
Waist circumference (cm) 86.3 ± 9.4 89.5 ± 9.7 <0.0001
Current drinker (n, %) 344 (18.1) 40 (20.2) 0.58
Current smoker (n, %) 382 (20.1) 39 (19.7) 0.81
SBP (mmHg) 134 ± 24 144 ± 27 <0.0001
DBP (mmHg) 78 ± 10 81 ± 10 0.001
Triglyceride (mmol/l) 1.40 (0.96–2.02) 1.48 (1.01–2.41) 0.02
LDL-C (mmol/l) 2.40 ± 0.68 2.35 ± 0.68 0.30
HDL-C (mmol/l) 1.37 ± 0.30 1.34 ± 0.31 0.31
Total cholesterol (mmol/l) 5.15 ± 0.96 5.11 ± 1.05 0.64
FPG (mmol/l) 5.1 (4.7–5.8) 5.6 (5.0–7.0) <0.0001
HbA1c (%) 6.1 (5.7–6.5) 6.4 (5.9–7.6) <0.0001
TSH (μIU/ml) 1.44 (1.03–2.14) 1.44 (1.01–2.07) 0.35
FT3 (pmol/l) 4.65 ± 0.55 4.72 ± 1.11 0.16
FT4 (pmol/l) 14.27 ± 1.80 14.85 ± 2.36 <0.0001
TPOAb (IU/ml) 0.30 (0.17–0.73) 0.32 (0.18–0.71) 0.55
TGAb (IU/ml) 1.06 (0.71–2.44) 0.93 (0.71–1.91) 0.09
eGFR (ml/min/1.73 m2) 92.4 ± 12.2 88.9 ± 14.4 0.0001
Urinary ACR (mg/g) 4.67 (2.39–8.71) 9.57 (4.41–16.87) <0.0001
Use of antidiabetic drugs 
(n, %)
208 (10.9) 52 (26.3) <0.0001
Use of antihypertensive 
drugs (n, %)
426 (22.4) 63 (31.8) 0.003
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function over time, whereas hyperthyroidism conveyed a 
harmful effect [21]. In addition, other perspective stud-
ies also demonstrated that overt and subclinical hypo-
thyroidism in older age (>85 years old) might even have 
a protective effect, particularly on span of life [28, 29]. 
However, our findings were conflicted with the results 
from the Kangbuk Samsung Health Study (KSHS), which 
was performed among 104,633 Korean participants with 
an average age of 38.0 years old and normal thyroid func-
tion at baseline. It reported that high-normal levels of 
TSH and low-normal FT3 levels below 3 pg/ml, but not 
FT4 levels, were associated with increased risk of inci-
dent CKD, defined as eGFR <60  mL/min/1.73  m2 [20]. 
The disparate definitions of CKD might be a possible 
attributor for this discrepancy. In our study, we defined 
CKD not only on basis of eGFR but also on the presence 
of albuminuria. Albuminuria would be induced by high 
thyroid function and then could deteriorate renal func-
tion gradually [17, 30]. In addition, it might be due to the 
relatively older participants in our study than those in 
KSHS. With the increasing age, renal function declined 
[31] and thyroid function changed including increase of 
serum TSH and FT4, and decrease of total triiodothyro-
nine [32].
In our study, we found that high levels of FT4, but not 
low levels of TSH, associated with incident CKD and rapid 
eGFR decline. Analogously, Ahmed MM reported that high 
levels of FT4, but not low levels of TSH, significantly associ-
ated with increasing severity of renal failure in patients with 
chronic renal failure and averagely aged 61 years old [33]. It 
might be partially due to the reduced sensitivity of pituitary 
with the increasing age; and then high FT4 levels could not 
generate negative feedback to TSH and suppress secretion 
of TSH [32, 34]. As shown in our study, serum FT4 was 
positively associated with age (β = 0.012, P = 0.0086), but 
TSH was not (β = −0.0021, P = 0.27).
However, the mechanisms of the positive associations 
of serum FT4 levels with incident CKD and rapid eGFR 
decline remain unclear. It might be due to the fact that 
high thyroid hormone levels increased the permeability 
of the glomerular barrier, and subsequently led to pro-
teinuria [35]. Several studies have reported that overt 
proteinuria was observed in hyperthyroid rats, as well as 
in Graves’ disease patients [36]. It may also be possible 
Table 2 Association of thyroid hormone levels with incident CKD
Model 1: adjusted for age, sex, BMI at baseline
Model 2: further adjusted for triglyceride, HDL-c, diabetes and hypertension status, current smoking and drinking status, use of antihypertensive drugs, use of 
antidiabetic drugs, urinary ACR, eGFR at baseline
Model 3: further adjusted for TPOAb, TGAb at baseline
P for trend values for percentages of incident CKD are calculated by using Cochran–Mantel–Haenszel (CMH) method
Data are odds ratios (95% confidence intervals)
ACR albumin-to-creatinine ratio, BMI body mass index, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, FT3 free triiodothyronine, FT4 free 
thyroxine, HDL-c high-density lipoprotein cholesterol, TSH thyroid-stimulating hormone, TPOAb thyroid peroxidase antibody, TGAb thyroglobulin antibody
Case/number (%) Model 1 Model 2 Model 3
Serum FT4
 Tertile 1 47/699 (6.7) 1.00 1.00 1.00
 Tertile 2 60/701 (8.6) 1.28 (0.86–1.91) 1.26 (0.83–1.91) 1.24 (0.82–1.88)
 Tertile 3 91/703 (12.9) 1.97 (1.36–2.86) 1.91 (1.30–2.81) 1.88 (1.27–2.77)
 P for trend <0.0001 0.0003 0.0008 0.001
 Each 1-pmol/l increase in FT4 198/2103 (9.4) 1.13 (1.05–1.21) 1.12 (1.04–1.20) 1.12 (1.05–1.20)
Serum FT3
 Tertile 1 65/687 (9.5) 1.00 1.00 1.00
 Tertile 2 68/712 (9.6) 1.07 (0.74–1.53) 1.11 (0.76–1.62) 1.12 (0.76–1.63)
 Tertile 3 65/704 (9.2) 1.09 (0.75–1.59) 1.06 (0.72–1.57) 1.04 (0.70–1.54)
 P for trend 0.88 0.64 0.76 0.86
 Each 1-pmol/l increase in FT3 198/2103 (9.4) 1.23 (1.01–1.49) 1.21 (0.99–1.49) 1.20 (0.98–1.47)
Serum TSH
 Tertile 1 64/700 (9.1) 1.00 1.00 1.00
 Tertile 2 74/700 (10.6) 1.13 (0.79–1.61) 1.31 (0.90–1.90) 1.34 (0.92–1.94)
 Tertile 3 60/703 (8.5) 0.86 (0.59–1.26) 0.99 (0.66–1.47) 1.04 (0.69–1.56)
 P for trend 0.70 0.45 0.99 0.80
 Each 1-μIU/ml increase in TSH 198/2103 (9.4) 0.99 (0.91–1.07) 0.99 (0.92–1.07) 1.00 (0.94–1.07)
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that the presence of albuminuria could promote renal 
function deterioration. Previous studies found that the 
elevated ACR, even within normal range, was associated 
with a faster decline in eGFR [37, 38].
The major strength of our study is the prospective 
nature. We also carefully performed adjustments for the 
potential confounders, including the autoimmune thy-
roid antibodies. Besides, the CKD was defined based on 
either eGFR <60 ml/min/1.73 m2 or presence of albumi-
nuria recommended by the 2012 KDIGO clinical prac-
tice guideline. The rationales arise from the evidence that 
decrease eGFR or albuminuria were consistently associ-
ated with increased risk of death, end stage renal disease 
or cardiovascular mortality [39]. However, several limi-
tations should be acknowledged. Firstly, the GFR was 
estimated by the 2009 CKD-EPI equation, rather than 
the gold standard of GFR measurement, a technetium 
99m diethylene-triaminepentaacetic acid (99mTc-DTPA) 
renal dynamic imaging method. However, the accu-
racy of CKD-EPI equation to estimate GFR has already 
been confirmed and validated in many previous studies 
[40, 41]. Secondly, urinary albumin and creatinine were 
measured using a single spot urine sample. However, it 
Table 3 Association of thyroid hormones with rapid eGFR decline during follow-up
Model 1: adjusted for age, sex, BMI at baseline
Model 2: further adjusted for triglyceride, HDL-c, diabetes and hypertension status, current smoking and drinking status, use of antihypertensive drugs, use of 
antidiabetic drugs, eGFR at baseline
Model 3: Further adjusted for TPOAb, TGAb at baseline
P for trend values for percentages of rapid eGFR decline are calculated by using Cochran–Mantel–Haenszel (CMH) method
Data are odds ratios (95% confidence intervals)
BMI body mass index, eGFR estimated glomerular filtration rate, FT3 free triiodothyronine, FT4 free thyroxine, HDL-c high-density lipoprotein cholesterol, TSH thyroid-
stimulating hormone, TPOAb thyroid peroxidase antibody, TGAb thyroglobulin antibody
Case/number (%) Model 1 Model 2 Model 3
Serum FT4
 Tertile 1 40/699 (5.7) 1.00 1.00 1.00
 Tertile 2 56/701 (8.0) 1.40 (0.92–2.14) 1.38 (0.89–2.12) 1.40 (0.91–2.16)
 Tertile 3 69/703 (9.8) 1.72 (1.15–2.59) 1.61 (1.06–2.45) 1.64 (1.07–2.50)
 P for trend 0.0004 0.009 0.03 0.02
 Each 1-pmol/l increase in FT4 165/2103 (7.9) 1.12 (1.05–1.21) 1.10 (1.02–1.18) 1.10 (1.03–1.18)
Serum FT3
 Tertile 1 55/687 (8.0) 1.00 1.00 1.00
 Tertile 2 69/712 (9.7) 1.29 (0.89–1.87) 1.35 (0.91–1.99) 1.36 (0.92–2.00)
 Tertile 3 41/704 (5.8) 0.79 (0.51–1.21) 0.84 (0.54–1.30) 0.83 (0.53–1.30)
 P for trend 0.025 0.33 0.50 0.49
 Each 1-pmol/l increase in FT3 165/2103 (7.9) 1.17 (0.95–1.44) 1.14 (0.93–1.40) 1.13 (0.92–1.39)
Serum TSH
 Tertile 1 63/700 (9.0) 1.00 1.00 1.00
 Tertile 2 53/700 (7.6) 0.77 (0.53–1.14) 0.85 (0.57–1.26) 0.85 (0.57–1.26)
 Tertile 3 49/703 (7.0) 0.67 (0.44–0.99) 0.75 (0.50–1.15) 0.74 (0.49–1.14)
 P for trend 0.35 0.046 0.18 0.17
 Each 1-μIU/ml increase in TSH 165/2103 (7.9) 0.97 (0.88–1.08) 1.00 (0.92–1.08) 1.00 (0.92–1.08)
Table 4 Association of  baseline FT4 with  predicted risks 
for future outcomes of incident CKD
Model 1: adjusted for age, sex, BMI at baseline
Model 2: further adjusted for triglyceride, HDL-c, diabetes and hypertension 
status, current smoking and drinking status, use of antihypertensive drugs, use 
of antidiabetic drugs, urinary ACR, eGFR, TPOAb and TGAb at baseline
Data are odds ratios (95% confidence intervals), calculated by using multinomial 
logit regression analysis, referenced to low risk of prognosis of incident CKD
ACR albumin-to-creatinine ratio, BMI body mass index, CKD chronic kidney 
disease, eGFR estimated glomerular filtration rate, FT4 free thyroxine, HDL-c 
high-density lipoprotein cholesterol, TPOAb thyroid peroxidase antibody, TGAb 
thyroglobulin antibody





and very high increased 
risk
Case/number (%) 177/2103 (8.4) 21/2103 (1.0)
Each 1-pmol/l increase in FT4
 Model 1 1.12 (1.04–1.21) 1.18 (1.05–1.34)
 Model 2 1.11 (1.03–1.19) 1.22 (1.06–1.41)
Each 1-tertile increase in FT4
 Model 1 1.33 (1.09–1.61) 2.73 (1.41–5.27)
 Model 2 1.30 (1.06–1.59) 2.61 (1.32–5.16)
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was more practicable in large epidemiological studies 
[6], and was highly agree with the 24-h urinary albumin 
excretion [42, 43]. Thirdly, there were only two measure-
ments of eGFR rather than repeated measurements of 
eGFR during follow-up. Fourthly, the current study was 
conducted in middle-aged and elderly Chinese adults. 
Hence, more cautions are needed to generalize the find-
ings to other age and ethnic groups.
Conclusions
In conclusion, the present study indicated that a high 
level of serum FT4, rather than serum TSH and FT3, was 
associated with increased risk of incident CKD, rapid 
eGFR decline and increased risks of concurrent com-
plications and further outcomes of CKD. Further stud-
ies aimed to validate our findings in other age and other 
ethnic groups, to examine the association of develop-
ing hyperthyroidism with incident CKD, and to explore 
related mechanisms are warranted in the future.
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